Reducing lipid levels in high-risk patients can significantly reduce disease burden and, depending on final negotiated prices, PCSK9 inhibitors can make an economic contribution to this goal.
Thanh G.N. Ton, PhD
Advertisement
Articles by Thanh G.N. Ton, PhD
Advertisement
Latest Updated Articles
- Value of Improved Lipid Control in Patients at High Risk for Adverse Cardiac Events
Published: June 15th 2016 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
Cytokines Linked With Drug Resistance in Ovarian Cancer, but Underlying Mechanisms Remain Unclear
2
Mepolizumab Reduces Health Care Resource Utilization, Work Impairment in Severe Asthma
3
Energy Insecurity Linked to Higher Depression, Anxiety in US Adults
4
FDA Expands Sotatercept Indication for PAH
5
